

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000383 A2

(51) International Patent Classification⁷: **A61L 31/10**,
27/34

(74) Agent: **KERRIGAN, Cameron**; Squire, Sanders &
Dempsey L.L.P., 600 Hansen Way, Palo Alto, CA
94303-1043 (US).

(21) International Application Number:
PCT/US2003/015544

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 14 May 2003 (14.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/176,504 21 June 2002 (21.06.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **ADVANCED CARDIOVASCULAR SYS-
TEMS, INC** [US/US]; 3200 Lakeside Drive, Santa Clara,
CA 95054 (US).


(72) Inventors: **ROORDA, Wouter, E.**; 36 Roosevelt Circle,
Palo Alto, CA 94306 (US). **DING, Ni**; 4103 Cortona Court,
San Jose, Ca 95135 (US). **PACETTI, Stephen, D.**; 4578
Madoc Way, San Jose, CA 95130 (US). **MICHAL, Eu-
gene, T.**; 56 Lower Terrace, San Francisco, CA 94114
(US). **SHAH, Ashok, A.**; 1571 Four Oaks Road, San Jose,
CA 95131 (US).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: POLYACRYLATES COATINGS FOR IMPLANTABLE MEDICAL DEVICES



(57) Abstract: A coating for a medical device, particularly for a drug eluting stent, is described. The coating can include a polyacrylate, a blend of polyacrylates, or a blend of the polyacrylate with other polymers, for example, poly(ethylene-covinyl alcohol).

WO 2004/000383 A2

POLYACRYLATES COATINGS FOR IMPLANTABLE MEDICAL DEVICES

BACKGROUND OF THE INVENTION5 Field of the Invention

 This invention is directed to coatings for implantable medical devices, such as drug eluting vascular stents.

Description of the State of the Art

10 Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced percutaneously into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion.

15 Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the lumen wall. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.

 A problem associated with the above procedure includes formation of

20 intimal flaps or torn arterial linings which can collapse and occlude the conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the

chance of the development of thrombosis and restenosis, a stent is implanted in the lumen to maintain the vascular patency.

Stents are used not only as a mechanical intervention but also as a vehicle for providing biological therapy. As a mechanical intervention, stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway. Typically, stents are capable of being compressed, so that they can be inserted through small vessels via catheters, and then expanded to a larger diameter once they are at the desired location. Examples in patent literature disclosing stents which have been applied in PTCA procedures include stents illustrated in U.S. Patent No. 4,733,665 issued to Palmaz, U.S. Patent No. 4,800,882 issued to Gianturco, and U.S. Patent No. 4,886,062 issued to Wiktor.

Biological therapy can be achieved by medicating the stents. Medicated stents provide for the local administration of a therapeutic substance at the diseased site. In order to provide an efficacious concentration to the treated site, systemic administration of such medication often produces adverse or toxic side effects for the patient. Local delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. Local delivery thus produces fewer side effects and achieves more favorable results. One proposed method for medicating stents involves the use of a polymeric carrier coated onto the surface of a stent. A solution which includes a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the blend is applied to the stent. The solvent is allowed to evaporate, leaving on the stent surface a coating of the polymer and the therapeutic substance impregnated in the polymer. The

embodiments of the invention provide coatings for implantable devices, such as stents, and methods of coating the same.

SUMMARY

5 A coating for an implantable medical device is provided, the coating comprises a thermoplastic polyacrylate material free from acetate species and a therapeutically active agent incorporated therein. The polyacrylate material can include homopolymers, copolymers or terpolymers of alkylacrylates or alkylmethacrylates, and blends thereof. The polyacrylate material can be poly(*n*-
10 butyl methacrylate). The polyacrylate material can include non-acrylate polymers such as fluorinated polymers or poly(ethylene-co-vinyl alcohol).

 According to another embodiment of this invention, a coating for an implantable medical device is provided, the coating comprises a first layer having an active agent incorporated therein and a second layer disposed over the first
15 layer, wherein the second layer comprises a thermoplastic polyacrylate material for modifying the rate of release of the agent.

 According to yet another embodiment of the invention, a method of coating an implantable medical device is provided, the method comprises depositing a first layer on the device, the first layer including an active agent for
20 the sustained release of the agent, and depositing a second layer over the first layer, the second layer comprising a thermoplastic polyacrylate material for modifying the rate of release of the agent.


BRIEF DESCRIPTION OF THE DRAWINGS

FIGs. 1 and 2 are graphs illustrating a profile of a rate of release of a drug from stents coated according to a method of the present invention.

DETAILED DESCRIPTION

5 A coating for an implantable medical device, such as a stent, according to one embodiment of the present invention, can include a drug-polymer layer, an optional topcoat layer, and an optional primer layer. The drug-polymer layer can be applied directly onto the stent surface to serve as a reservoir for a therapeutically active agent or drug which is incorporated into the drug-polymer
10 layer. The topcoat layer, which can be essentially free from any therapeutic substances or drugs, serves as a rate limiting membrane which further controls the rate of release of the drug. The optional primer layer can be applied between the stent and the drug-polymer layer to improve the adhesion of the drug-polymer layer to the stent.

15 According to one embodiment of the present invention, polymers of esters having the general formula (I)



(I) or blends thereof, can be used for making the stent coatings.

In formula (I), X, X', and X'' is each, independently, a hydrogen atom
20 (acrylates) or an alkyl group, such as a methyl group CH₃ (methacrylates); R, R' and R'' is each, independently, a C₁ to C₁₂ straight chained or branched aliphatic radical; "m" is an integer larger than 1, and "n" and "p" is each 0 or an integer. If both n = 0 and p = 0, the polymer of formula (I) is a homopolymer (i.e., PBMA). If n ≠ 0 and p = 0, or n = 0 and p ≠ 0, the polymer of formula (I) is a copolymer,
25 and if n ≠ 0 and p ≠ 0, the polymer of formula (I) is a terpolymer.

Polymers of formula (I) can be used for making either the drug-polymer layer, the topcoat membrane, the optional primer layer, or any combination thereof. For the purposes of the present invention, such polymers, or blends thereof, are defined as "polyacrylates" or as "polyacrylate materials."

5 One example of a polyacrylate suitable for fabricating either the drug-polymer layer or the topcoat membrane is poly(*n*-butyl methacrylate) (PBMA), described by formula (I) where
 $X = CH_3$, $n = 0$, $p = 0$, and "R" is a *n*-butyl radical C_4H_9 ($-CH_2-CH_2-CH_2-CH_3$). PBMA has good biocompatibility, is soluble in many common solvents, has good
10 mechanical and physical properties, and adheres well to the underlying stent surface or the primer layer. PBMA is available commercially from Aldrich Chemical Co. of Milwaukee, Wisconsin, and from Esschem, Inc. of Lynwood, Pennsylvania.

 The rate of release of the drug through the polymer, such as the topcoat
15 membrane, is related to the rate of diffusion of the drug through the matrix. The slower the rate of diffusion, the greater the polymer's ability to prolong the rate of release and the residence time of the drug at the implantation site. The rate of diffusion is in turn related to the water adsorption rate, the degree of crystallinity, if any, and the glass transition temperature (T_g) of the polymer.

20 As a general rule, the more the polymer absorbs water at body temperature, the faster the drug diffuses out from the polymer, and the greater degree of crystallinity of the polymer's structure, the slower a drug will diffuse out of the polymer. Since all of the R, R' and R" groups in these polyacrylates are aliphatic, the water adsorption tends to be low. One common technique for producing these
25 polymers is by free radical polymerization yielding amorphous polymers with no

crystallinity. Hence, it is the glass transition temperature that is one of important discriminating characteristic for these polymers.

Consequently, the present invention allows manipulating the rate of release of the drug into the blood stream by varying T_g of the polymer or the blend of polymers forming the drug-polymer layer and/or the membrane. Typically, it is desirable to decrease the rate of release. In order to do so, the polyacrylates having higher values of T_g can be used. Examples of such polyacrylates include poly(methyl methacrylate) ($T_g = 105^\circ\text{C}$) and poly(*tert*-butyl methacrylate) ($T_g = 107^\circ\text{C}$).

However, if it is desirable to increase the rate of release, the polyacrylates having low values of T_g can be used. PBMA is one of such polyacrylates having the T_g of about 20°C . Examples of other suitable polyacrylates having low T_g include poly(*n*-hexyl methacrylate) ($T_g = -5^\circ\text{C}$) and poly(methyl acrylate) ($T_g = 9^\circ\text{C}$).

For a copolymer of these polyacrylates, the T_g (on the Kelvin scale) is generally the mass fraction-weighted average of the constituent components of the copolymer. Consequently, a copolymer or terpolymer of formula (I) with predetermined higher or lower value of T_g can be used as drug-polymer layer and/or a topcoat membrane, thus providing a desirable lower or higher rate of release of the drug, respectively. For example, a random poly(methyl methacrylate-co-*n*-butyl methacrylate) [P(MMA-BMA)], having about 30 molar percent of methyl methacrylate-derived units and about 70 molar percent of *n*-butyl methacrylate-derived units, has a theoretical T_g of about 45.5°C . Therefore, a topcoat membrane made of P(MMA-BMA) will provide faster drug release than

pure PMMA but slower than pure PBMA. Similarly, blends of individual polyacrylates, e.g., PBMA and PMMA can be used.

Some examples of polyacrylates that are suitable for fabrication of the coating, e.g., the drug-polymer layer and/or the topcoat membrane, are

5 summarized in Table 1.

Table 1. Examples of Polyacrylates $-\text{[CH}_2\text{-C(X)(COOR)]}_m\text{-[CH}_2\text{-C(X')(COOR')]}_n\text{-}$ Suitable for Fabricating Stent Coatings

No.	Polyacrylate	Abbreviation	R	X	m	R'	X'	n	T _g , °C
1	Poly(<i>n</i> -butyl methacrylate)	PBMA	<i>i</i> -C ₄ H ₉	CH ₃	>1	N/A	N/A	0	20
2	Poly(<i>iso</i> -butyl methacrylate)	Pi-BMA	<i>i</i> -C ₄ H ₉	CH ₃	>1	N/A	N/A	0	66
3	Poly(<i>tert</i> -butyl methacrylate)	PBMA	<i>tert</i> -C ₄ H ₉	CH ₃	>1	N/A	N/A	0	107
4	Poly(methyl methacrylate)	PMMA	CH ₃	CH ₃	>1	N/A	N/A	0	105
5	Poly(ethyl methacrylate)	PEMA	C ₂ H ₅	CH ₃	>1	N/A	N/A	0	63
6	Poly(<i>n</i> -propyl methacrylate)	PPMA	<i>n</i> -C ₃ H ₇	CH ₃	>1	N/A	N/A	0	35
7	Poly(methyl acrylate)	PMA	CH ₃	H	>1	N/A	N/A	0	9
8	Poly(<i>n</i> -hexyl methacrylate)	PHMA	<i>n</i> -C ₆ H ₁₃	CH ₃	>1	N/A	N/A	0	-5
9	Poly(methyl methacrylate-co- <i>n</i> -butyl methacrylate)	P(MMA- <i>BMA</i>)	CH ₃	CH ₃	30	<i>n</i> -C ₄ H ₉	CH ₃	70	46
10	Poly(<i>n</i> -butyl methacrylate-co- <i>iso</i> -butyl methacrylate)	P(<i>BMA-i-BMA</i>)	<i>n</i> -C ₄ H ₉	CH ₃	50	<i>i</i> -C ₄ H ₉	CH ₃	50	35

Only homo- and copolymers are listed in Table 1 (that is, the polymers of formula (I) where $p = 0$), but it should be understood that terpolymers corresponding to formula (I) (when $n \neq 0$ and $p \neq 0$) can be used as well.

To fabricate the coating, one of the polyacrylates, or a blend thereof can be applied on the stent using commonly used techniques known to those having ordinary skill in the art. For example, the polyacrylate can be applied to the stent by dissolving the polymer in a solvent, or a mixture of solvents, and applying the resulting solution on the stent by spraying or immersing the stent in the solution.

Representative examples of some suitable solvents include N,N-dimethylacetamide (DMAC), N,N-dimethylformamide (DMF), tetrahydrofuran (THF), cyclohexanone, xylene, toluene, acetone, methyl ethyl ketone, propylene glycol monomethyl ether, methyl butyl ketone, ethyl acetate, *n*-butylacetate, and dioxane. Examples of suitable mixtures of solvents include mixtures of DMAC and methanol (e.g., a 50:50 by mass mixture), cyclohexanone and acetone (e.g., 80:20, 50:50, 20:80 by mass mixtures), acetone and xylene (e.g. a 50:50 by mass mixture), and acetone, FLUX REMOVER AMS, and xylene (e.g., a 10:50:40 by mass mixture). FLUX REMOVER AMS is trade name of a solvent manufactured by Tech Spray, Inc. of Amarillo, Texas comprising about 93.7% of a mixture of 3,3-dichloro-1,1,1,2,2-pentafluoropropane and 1,3-dichloro-1,1,2,2,3-pentafluoropropane, and the balance methanol, with trace amounts of nitromethane.

In addition, blends of polyacrylates with polymers other than polyacrylates can be used to fabricate the coating. In one embodiment, the blend of polyacrylates with non-acrylate materials is free from acetate species. Poly(ethylene-co-vinyl alcohol) (EVAL) is one example of a suitable non-

acrylate polymer. EVAL has the general formula $-\text{[CH}_2\text{-CH}_2\text{]}_q\text{[CH}_2\text{-CH(OH)]}_r\text{-}$, where "q" and "r" is each an integer. EVAL may also include up to 5 molar % of units derived from styrene, propylene and other suitable unsaturated monomers. A brand of copolymer of ethylene and vinyl alcohol distributed commercially under the trade name EVAL by Aldrich Chemical Co., or manufactured by EVAL Company of America of Lisle, Illinois, can be used.

Examples of other polymers with which polyacrylates can be blended include fluorinated polymers, such as poly(vinylidene fluoride) (PVDF) and poly(vinylidene fluoride-co-hexafluoro propene) (PVDF-HFP). The blend of a polyacrylate and a fluorinated polymer can contain between about 10 and about 95% (mass) of the fluorinated polymer.

The polyacrylates can be used to manufacture the primer layer, drug-polymer layer, topcoat membrane, or all three layers. For example, the polyacrylates can be used to make both the drug-polymer layer and the topcoat membrane, but not the primer layer. Any combination of the three layers can include a polyacrylate, so long as at least one of the layers includes the material. If a polyacrylate is used to make only one of the layers, the other layer or layers can be made of an alternative polymer.

Representative examples of suitable alternative polymers include EVAL, poly(hydroxyvalerate), poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane; poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), co-poly(ether-esters) (e.g. PEO/PLA),

polyalkylene oxalates, polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers other than polyacrylates, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene halides (such as polyvinylidene fluoride and polyvinylidene chloride), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers), polyamides (such as Nylon 66 and polycaprolactam), alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose.

15 The coating of the present invention has been described in conjunction with a stent. However, the coating can also be used with a variety of other medical devices. Examples of the implantable medical device, that can be used in conjunction with the embodiments of this invention include stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, axius coronary shunts and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation). The underlying structure of the device can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt-chromium alloys (e.g., ELGILOY), stainless steel (316L), "MP35N," "MP20N," ELASTINITE (Nitinol),
20 tantalum, tantalum-based alloys, nickel-titanium alloy, platinum, platinum-based
25

alloys such as, e.g., platinum-iridium alloy, iridium, gold, magnesium, titanium, titanium-based alloys, zirconium-based alloys, or combinations thereof. Devices made from bioabsorbable or biostable polymers can also be used with the embodiments of the present invention.

5 “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co. of Jenkintown, Pennsylvania. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.

10 The active agent or the drug can include any substance capable of exerting a therapeutic or prophylactic effect for a patient. The drug may include small molecule drugs, peptides, proteins, oligonucleotides, and the like. The active agent could be designed, for example, to inhibit the activity of vascular smooth muscle cells. It can be directed at inhibiting abnormal or inappropriate migration
15 and/or proliferation of smooth muscle cells to inhibit restenosis. Examples of drugs include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof. Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I₁, actinomycin X₁, and actinomycin C₁. The active agent can also fall under the genus of antineoplastic, anti-inflammatory,
20 antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel, docetaxel, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin, hydrochloride, and mitomycin. Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium

heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin. Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril, cilazapril or lisinopril, calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (ω -3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon; genetically engineered epithelial cells; rapamycin and structural derivatives or functional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin (known by the trade name of Everolimus available from Novartis) 40-O-(3-hydroxy)propyl-rapamycin and 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin; tacrolimus; and dexamethasone.

20

EXAMPLES

Some embodiments of the present invention are illustrated by the following Examples.

Example 1

A polymer solution containing between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of EVAL and the balance, DMAC solvent, can be prepared. The solution can be applied onto a stent to form a
5 primer layer. To apply the primer layer, a spray apparatus, such as an EFD 780S spray nozzle with a VALVEMATE 7040 control system, manufactured by EFD, Inc. of East Providence, Rhode Island can be used. The EFD 780S spray nozzle is an air-assisted external mixing atomizer. The composition is atomized by air and applied to the stent surfaces. During the process of applying the composition, the
10 stent can be optionally rotated about its longitudinal axis, at a speed of 50 to about 150 rpm. The stent can also be linearly moved along the same axis during the application.

The EVAL solution can be applied to a 13-mm TETRA stent (available from Guidant Corporation) in a series of 10-second passes, to deposit, for example,
15 10 µg of coating per spray pass. Instead of the 13-mm TETRA stent, another suitable stent can be used, for example, a 12-mm VISION stent (also available from Guidant Corporation). Between the spray passes, the stent can be dried for about 10 seconds using flowing air with a temperature of about 60°C. Five spray passes can be applied, followed by baking the primer layer at about 140°C for one
20 hour. As a result, a primer layer can be formed having a solids content of about 50 µg. "Solids" means the amount of the dry residue deposited on the stent after all volatile organic compounds (e.g., the solvent) have been removed.

A drug-containing formulation can be prepared comprising:

(a) between about 0.1 mass % and about 15 mass %, for example, about 2.0
25 mass % of EVAL;

(b) between about 0.1 mass % and about 2 mass %, for example, about 1.0 mass % of an active agent, for example, Everolimus; and

(c) the balance, a solvent mixture of DMAC and pentane, the solvent mixture containing about 80 (mass) % of DMAC and about 20 (mass) % of pentane.

5 In a manner identical to the application of the primer layer, five spray passes can be performed, followed by baking the drug-polymer layer at about 50°C for about 2 hours, to form the drug-polymer layer having a solids content between about 30 µg and 750 µg, for example, about 90 µg, and a drug content of between about 10 µg and about 250 µg, for example, 30 µg.

10 Finally, a topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % PBMA and the balance a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS, and xylene. In a manner identical to the application of the primer layer and the
15 drug-polymer layer, a number of spray passes are performed followed by final baking at about 50°C for about 2 hours. As a result, the topcoat membrane can be formed, the membrane having a solids content of between about 30 µg and about 350 µg, for example, about 50 µg.

Example 2

20 A stent was coated as described in Example 1, except instead of the Everolimus, estradiol was used. The coated stent was tested for a study of the drug release. The stent was immersed for 24 hours in bovine serum. The drug was extracted, and the amount of estradiol released after 24 hours was measured chromatographically (by HPLC). The results of this study are summarized in
25 Table 2.

Table 2. Drug Release Study of Stent Coatings Having PBMA Topcoat Membranes (EVAL-based Drug-Polymer Layer, Estradiol Drug)

No.	Topcoat Membrane Solids, μg	Drug Loaded in the Drug-Polymer Layer, μg	% of the Drug Released in 24 Hours
1	30	240	15.0
2	50	240	13.0
3	100	240	11.0
4	160	240	4.3
5	300	170	1.5

Further, a kinetic study of the drug release profile was conducted. The stent had the total amount of solids of the topcoat membrane of about 160 μg and the total amount of estradiol in the drug-polymer layer of about 30 μg . The stent was immersed in a phosphate buffered saline solution having 1 mass % of sodium dodecyl sulfate. A sample of the solution was taken every 20 minutes and analyzed by HPLC for the amount of estradiol released.

As seen from the release profile for three different coated stents shown on FIG. 1, after 10 days about 50 mass % of estradiol was released in an almost perfect linear profile indicating a topcoat layer-controlled zero-order type of release. The small burst in the first 24 hours is due to the saturation of the topcoat layer with the drug. Once a stable state was established, the release rate remained

constant for 240 hours. The linear correlation coefficient between 24 and 240 hours was 0.997.

Example 3

- A stent was coated as described in Example 1, except instead of
- 5 Everolimus, etoposide was used. The coated stent was tested for a study of the drug release as described in Example 2. The results of this study are summarized in Table 3.

Table 3. Drug Release Study of Stent Coatings Having PBMA Topcoat Membranes (EVAL-based Drug-Polymer Layer, Etoposide Drug)

No.	Topcoat Membrane Solids, μg	Topcoat Membrane Thickness, μm	Stent	Drug Loaded in the Drug-Polymer Layer, μg	Amount of the Drug Released in 24 Hours, μg	% of the Drug Released in 24 Hours
1	30	0.54	12 mm VISION	240	139	57.9
2	50	0.89	12 mm VISION	240	58	24.2
3	100	1.30	12 mm VISION	240	24	10.0
4	50	0.61	13 mm TETRA	180	148	82.2
5	120	1.46	13 mm TETRA	180	70	38.9
6	200	2.44	13 mm TETRA	180	72	40.0
7	200	2.44	13 mm TETRA	180	41	22.7
8	300	3.86	13 mm TETRA	180	50	27.8

A kinetic study of the drug release profile was conducted. The stent was immersed in a phosphate-buffered saline solution having about 1 mass % of sodium dodecyl sulfate. The solution was frequently sampled and the drug concentration was measured using HPLC. The stent had the total amount of solids of the topcoat membrane of about 30 μg and the total amount of estradiol in the drug-polymer layer of about 160 μg . As seen from the release profile for three different coated stents shown on FIG. 2, the profile was close to linear and the reproducibility was excellent.

Example 4

A primer layer can be applied onto a stent as described in Example 1. A drug formulation can be prepared comprising:

(a) between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of PBMA;

(b) between about 0.1 mass % and about 2 mass %, for example, about 1.6 mass % of a therapeutically active substance, for example, everolimus; and

(c) the balance, a solvent system, for example a 60:40 (mass) blend of acetone and xylene.

The drug containing formulation can then be applied to the stent, and a drug-polymer layer is formed, in a manner identical to that described in Example 1. The solids contents of the drug-polymer layer can be 1,200 μg .

Finally, a topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % PBMA and the balance a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER

AMS and xylene, and the topcoat membrane can be formed, in a manner identical to that described in Example 1. The topcoat membrane can have a solids content of between about 20 μg and about 200 μg , for example, about 30 μg .

5

Example 5

A primer layer can be applied onto a 8-mm stent as described in Example

1. A drug formulation can be prepared comprising:

(a) between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of PBMA;

10 (b) between about 0.1 mass % and about 2 mass %, for example, about 1.6 mass % of a therapeutically active substance, for example, Everolimus; and

(c) the balance, a solvent system, for example a 60:40 (mass) blend of acetone and xylene.

The drug formulation can then be applied onto the stent, and a drug-polymer
15 layer is formed in a manner identical to that described in Example 1. The solids contents of the drug-polymer layer can be 1,200 μg . In this Example, the stent coating has no separate topcoat membrane.

Example 6

20 A primer layer can be applied onto a 8-mm stent as described in Example

1. A drug formulation can be prepared comprising:

(a) between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of P(MMA-BMA) having a weight-average molecular weight M_w of about 150,000 available from Aldrich Chemical Company under the name PBM 150;

(b) between about 0.1 mass % and about 2 mass %, for example, about 1.0 mass % of an active agent, for example, Everolimus; and

(c) the balance, a solvent system, for example a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS and xylene.

PBM 150 contains about 79.2 mass % of units derived from BMA. The drug formulation can then be applied onto the dried primer layer, and a drug-polymer layer is formed, in a manner identical to that described in Example 1. The drug-polymer layer can have the total amount of solids of between about 300 and 600 μg , for example, about 520 μg . In this Example, the stent coating has no separate topcoat membrane.

15

Example 7

A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 1, the drug-polymer layer having the total amount of EVAL between about 300 and 800 μg , for example, about 325 μg . A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % P(MMA-BMA) having about 66.5 mass % of units derived from BMA, and the balance of a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS and xylene. The topcoat membrane can be formed having the total amount of solids between about 20 and 200 μg , for example, about 30 μg .

Example 8

A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 1, the drug-polymer layer having the total amount of EVAL between about 300 and 800 μg , for example, about 380 μg . A topcoat composition to
5 control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a 1:1 (by mass) blend of P(MMA-BMA) and PBMA, and the balance of a solvent system, for example, the solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX
10 REMOVER AMS and xylene. The P(MMA-BMA)/PBMA blend can have about 83.3 mass % of units derived from BMA. The topcoat membrane can be formed having the total amount of solids between about 20 and 200 μg , for example, about 30 μg .

Example 9

A primer layer and a drug-polymer layer can be applied onto a stent as
15 described in Example 1, the drug-polymer layer having the total amount of EVAL between about 300 and 800 μg , for example, about 350 μg . A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a 2:1 (by mass) blend of
20 P(MMA-BMA) and PBMA, and the balance a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS and xylene. The P(MMA-BMA)/PBMA blend can have about 77.8 mass % of units derived from BMA. The topcoat membrane can have a total amount of solids between about 20 and 200 μg , for example, about 28 μg .

Example 10

A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 9. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a 4:1 (by mass) blend of P(MMA-BMA) and PBMA, and the balance a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER AMS and xylene. The P(MMA-BMA)/PBMA blend can have about 73.3 mass % of units derived from BMA. The topcoat membrane can have a total amount of solids between about 20 and 200 μg , for example, about 32 μg .

Example 11

A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 9. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of PEMA, and the balance a solvent system, for example, a solvent system including a 80:20 (mass) blend of acetone and cyclohexanone. Poly(ethyl methacrylate) having a weight-average molecular weight M_w of about 101,400 available from Aldrich Chemical Company is one example of a brand of PEMA that can be used. In a manner identical to the application of the primer layer and the drug-polymer layer, the topcoat composition can be applied onto the dried drug-polymer layer. A number of spray passes can be performed followed by final baking, first at about 60°C for about 2 hours and then at about 140°C for about 1 hour. The topcoat membrane can be formed, the membrane having a solids content of between about 20 μg and about 300 μg , for example, about 40 μg .

Example 12

A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 9. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a blend of PEMA with a fluorinated polymer; and the balance a solvent system, for example, a solvent system including a 50:50 (mass) blend of acetone and cyclohexanone. The brand of PEMA described in Example 10 can be used. One example of the fluorinated polymer that can be used in a blend with PEMA is PVDF-HFP, such as SOLEF 21508 having about 85 mass % of vinylidene fluoride-derived units and about 15 mass % of hexafluoro propene-derived units. SOLEF 21508 is available from Solvay Fluoropolymers, Inc. of Houston, Texas. The PEMA/SOLEF 21508 blend can be 3:1 (mass) (containing about 75 mass % of PEMA and about 25 mass % of SOLEF 21508). In a manner identical to the application of the primer layer and the drug-polymer layer, the topcoat composition can be applied onto the dried drug-polymer layer. A number of spray passes can be performed followed by final baking, first at about 60°C for about 2 hours and then at about 100°C for about 1 hour. The topcoat membrane can have a solids content of between about 20 µg and about 300 µg, for example, about 42 µg.

Example 13

A stent was coated as described in Example 12, except instead of the 3:1 PEMA/SOLEF 21508 blend, a 3:1 (mass) blend of PEMA/PBMA can be used to form the topcoat membrane. The dry topcoat membrane can have a solids content of between about 20 µg and about 300 µg, for example, about 50 µg.

Example 14

A stent was coated as described in Example 13, except instead of the 3:1 PEMA/PBMA blend, a 1:1 (mass) blend of PEMA/PBMA can be used to form the topcoat membrane (containing about 50 mass % of PEMA and about 50 mass % of PBMA).

Example 15

A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 4. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a 1:1 (by mass) blend of PBMA and EVAL, and the balance a solvent system, for example, a solvent system including a 80:20 (mass) blend of DMAC and pentane. The topcoat membrane can have a total amount of solids of between about 20 and 200 μg , for example, about 30 μg .

Example 16

A primer layer can be applied onto a stent as described in Example 1. A drug formulation can be prepared comprising:

- (a) between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of a 1:1 (by mass) blend of PBMA and EVAL;
- (b) between about 0.1 mass % and about 2 mass %, for example, about 1.6 mass % of a therapeutically active substance, for example, Everolimus; and
- (c) the balance, a solvent system, for example, a solvent system which includes a 80:20 (mass) blend of DMAC and pentane.

The drug containing formulation can then be applied onto the stent. The solids contents of the drug-polymer layer can be 1,200 μg .

Example 17

5 A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 16. A topcoat composition to control the drug release rate can be prepared, comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % PBMA and the balance a solvent system, for example, a solvent system including a 10:50:40 (mass) blend of acetone, Techspray's FLUX REMOVER
10 AMS and xylene. The topcoat membrane can have a solids content of between about 20 μg and about 200 μg , for example, about 30 μg .

Example 18

 A primer layer and a drug-polymer layer can be applied onto a stent as
15 described in Example 16. A topcoat composition to control the drug release rate can be prepared as described in Example 15. The topcoat membrane can have a total amount of solids between about 20 and 200 μg , for example, about 30 μg .

Example 19

20 A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 1. A topcoat composition to control the drug release rate can be prepared as described in Example 15. The topcoat membrane can be formed, in a manner identical to that described in Example 1, the topcoat membrane having the total amount of solids between about 20 and 200 μg , for example, about 30 μg .

Example 20

A primer layer and a drug-polymer layer can be applied onto a stent as described in Example 16. A topcoat composition to control the drug release rate can be prepared, the composition comprising between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % EVAL and the balance DMAC solvent. The topcoat membrane can be formed, in a manner identical to that described in Example 1.

The information discussed in Examples 1-20 is summarized in Table 4.

10

Table 4. Summary of Examples 1-20

Example No	Polymer of the Drug-Polymer Layer	Drug	Polymer of the Topcoat Matrix
1	EVAL	Everolimus	PBMA
2	EVAL	Estradiol	PBMA
3	EVAL	Etoposide	PBMA
4	PBMA	Everolimus	PBMA
5	PBMA	Everolimus	None
6	P(MMA-BMA)	Everolimus	None
7	EVAL	Everolimus	P(MMA-BMA)
8	EVAL	Everolimus	1:1 blend of P(MMA-BMA) and PBMA
9	EVAL	Everolimus	2:1 blend of P(MMA-BMA) and PBMA
10	EVAL	Everolimus	4:1 blend of P(MMA-BMA) and PBMA
11	EVAL	Everolimus	PEMA
12	EVAL	Everolimus	3:1 blend of PEMA and P(VDF-HFP)

13	EVAL	Everolimus	3:1 blend of PEMA and PBMA
14	EVAL	Everolimus	1:1 blend of PEMA and PBMA
15	PBMA	Everolimus	1:1 blend of PBMA EVAL
16	1:1 blend of PBMA EVAL	Everolimus	None
17	1:1 blend of PBMA EVAL	Everolimus	PBMA
18	1:1 blend of PBMA EVAL	Everolimus	1:1 blend of PBMA EVAL
19	EVAL	Everolimus	1:1 blend of PBMA EVAL
20	1:1 blend of PBMA EVAL	Everolimus	EVAL

While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore,

5 the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

CLAIMS

WHAT IS CLAIMED IS:

1. A coating for an implantable medical device, comprising a thermoplastic polyacrylate material free from acetate species and a therapeutically active agent
5 incorporated therein.
2. The coating of Claim 1, wherein the implantable medical device is a stent.
3. The coating of Claim 1, wherein the therapeutically active agent is rapamycin, derivatives or analogs thereof.
4. The coating of Claim 1, wherein the polyacrylate material comprises
10 homopolymers, copolymers or terpolymers of alkylacrylates or alkylmethacrylates, and blends thereof.
5. The coating of Claim 4, wherein the alkyls of the alkylacrylates or alkylmethacrylates are selected from a group consisting of C₁-C₁₂ straight-chained or branched alkyls.
- 15 6. The coating of Claim 1, wherein the polyacrylate material is poly(*n*-butyl methacrylate).
7. The coating of Claim 1, wherein the polyacrylate material comprises blends of homopolymers, copolymers or terpolymers of alkylacrylates or alkylmethacrylates, and non-acrylate polymers.
- 20 8. The coating of Claim 7, wherein the non-acrylate polymers are selected from fluorinated polymers or poly(ethylene-co-vinyl alcohol).
9. The coating of Claim 8, wherein the fluorinated polymers are selected from a group consisting of poly(vinylidene fluoride) and poly(vinylidene fluoride-co-hexafluoropropene).

10. A coating for an implantable medical device, the coating comprising a first layer having an active agent incorporated therein and a second layer disposed over the first layer, wherein the second layer comprises a thermoplastic polyacrylate material for modifying the rate of release of the agent.
- 5 11. The coating of Claim 10, wherein the implantable medical device is a stent.
12. The coating of Claim 10, wherein the agent is for reducing, inhibiting or preventing restenosis.
13. The coating of Claim 10, wherein the polyacrylate material comprises homopolymers, copolymers or terpolymers of alkylacrylates or alkylmethacrylates,
10 and blends thereof.
14. The coating of Claim 13, wherein the alkyls of the alkylacrylates or alkylmethacrylates are selected from a group consisting of C₁-C₁₂ straight-chained or branched alkyls.
15. The coating of Claim 10, wherein the polyacrylate material is poly(*n*-butyl
15 methacrylate).
16. The coating of Claim 10, wherein the second layer additionally includes a non-acrylate polymer.
17. The coating of Claim 16, wherein the non-acrylate polymer is selected from fluorinated polymers or poly(ethylene-co-vinyl alcohol).
- 20 18. The coating of Claim 17, wherein the fluorinated polymers are selected from a group consisting of poly(vinylidene fluoride) or poly(vinylidene fluoride-co-hexafluoropropene).
19. A method of coating an implantable medical device, comprising depositing a first layer on the device, the first layer including an active agent for the sustained
25 release of the agent, and depositing a second layer over the first layer, the second

layer comprising a thermoplastic polyacrylate material for modifying the rate of release of the agent.

20. The method of Claim 19, wherein the implantable medical device is a stent.

21. The method of Claim 19, wherein active agent is rapamycin or derivatives
5 or analogs thereof.

22. The method of Claim 19, wherein the polyacrylate material comprises homopolymers, copolymers or terpolymers of alkylacrylates or alkylmethacrylates, and blends thereof.

23. The method of Claim 22, wherein the alkyls of the alkylacrylates or
10 alkylmethacrylates are selected from a group consisting of C₁-C₁₂ straight-chained or branched alkyls.

24. The method of Claim 19, wherein the polyacrylate material is poly(*n*-butyl methacrylate).

25. The method of Claim 19, wherein the second layer additionally comprises
15 a non-acrylate polymer.

26. The method of Claim 25, wherein the non-acrylate polymer is selected from fluorinated polymers or poly(ethylene-co-vinyl alcohol).

27. The method of Claim 26, wherein the fluorinated polymers are selected from a group consisting of poly(vinylidene fluoride) and poly(vinylidene
20 fluoride-co-hexafluoropropene).

1/2





FIG. 1

2/2

**FIG. 2**

SUBSTITUTE SHEET (RULE 26)

THIS PAGE BLANK (USPTO)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000383 A3

(51) International Patent Classification⁷: **A61L 31/10**,
27/34

(74) Agent: **KERRIGAN, Cameron**; Squire, Sanders &
Dempsey L.L.P., 600 Hansen Way, Palo Alto, CA
94303-1043 (US).

(21) International Application Number:
PCT/US2003/015544

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 14 May 2003 (14.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/176,504 21 June 2002 (21.06.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **ADVANCED CARDIOVASCULAR SYS-
TEMS, INC** [US/US]; 3200 Lakeside Drive, Santa Clara,
CA 95054 (US).

Published:

— with international search report

(72) Inventors: **ROORDA, Wouter, E.**; 36 Roosevelt Circle,
Palo Alto, CA 94306 (US). **DING, Ni**; 4103 Cortona Court,
San Jose, Ca 95135 (US). **PACETTI, Stephen, D.**; 4578
Madoc Way, San Jose, CA 95130 (US). **MICHAL, Eu-
gene, T.**; 56 Lower Terrace, San Francisco, CA 94114
(US). **SHAH, Ashok, A.**; 1571 Four Oaks Road, San Jose,
CA 95131 (US). **HOSSAINY, Syed, F., A.**; 34325 Tupelo
Street, Fremont, CA 94555 (US).

(88) Date of publication of the international search report:
27 May 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **POLYACRYLATES COATINGS FOR IMPLANTABLE MEDICAL DEVICES**

(57) Abstract: A coating for a medical device, particularly for a drug eluting stent, is described. The coating can include a polyacrylate, a blend of polyacrylates, or a blend of the polyacrylate with other polymers, for example, poly(ethylene-covinyl alcohol).

WO 2004/000383 A3

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 03/15544

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61L31/10 A61L27/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, PAJ, WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	"ROLLING THERAPEUTIC AGENT LOADING DEVICE FOR THERAPEUTIC AGENT DELIVERY OR COATED STENT" RESEARCH DISCLOSURE, KENNETH MASON PUBLICATIONS, HAMPSHIRE, GB, no. 434, June 2000 (2000-06), page 975, XP000980708 ISSN: 0374-4353 *entire document*	1,2,4,5
X	NOVICK, SCOTT J. ET AL: "Protein-containing hydrophobic coatings and films" BIOMATERIALS (2001), VOLUME DATE 2002, 23(2), 441-448, XP002252591 *abstract*	1,2,4,5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

3 September 2003

Date of mailing of the international search report

23. 01. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schnack, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/15544

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/29043 A (HABERBOSCH WERNER ;JUSTUS LIEBIG UNI GIESSEN (DE); CHRISTOPHE BURE) 25 May 2000 (2000-05-25) claims 1-26 examples 1-4 -----	1-5
X	US 2001/014717 A1 (HOSSAINY SYED F A ET AL) 16 August 2001 (2001-08-16) '0031!-'0042!, '0080! claims 1-36 -----	1,2,4,5
X	WO 99/55396 A (SURMODICS INC) 4 November 1999 (1999-11-04) page 4, line 1 - page 8, line 30 example 1 -----	1-9
X	WO 02/24249 A (BINDERMAN ITZHAK ;KOOLE LEVINAS H (NL)) 28 March 2002 (2002-03-28) page 4, line 5 - line 30 page 6, line 26 - page 8, line 11 page 12, line 1 - line 27 page 16, line 5 - page 17, line 8 -----	1,2,4,5 3
X	US 6 110 483 A (ZHANG XIANPING ET AL) 29 August 2000 (2000-08-29) column 3, line 65 - column 6, line 16 claims 1-40 -----	1-8
P,X	WO 03/022324 A (ABBOTT LAB) 20 March 2003 (2003-03-20) page 16, line 19 - page 17, line 22 -----	1,2,4,5 3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/15544

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-9

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-9

A coating for an implantable medical device, comprising a thermoplastic polyacrylate material free from acetate species and a herapeutically active agent incorporated therein.

2. claims: 10-27

A coating for an implantable medical device, the coating comprising a first layer having an active agent incorporated therein and a second layer disposed over the first layer, wherein the second layer comprise a thermoplastic polyacrylate material for modifying the rate of release of the agent.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/15544

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0029043	A	25-05-2000	FR 2785812 A1	19-05-2000
			AU 1168100 A	05-06-2000
			CA 2349930 A1	25-05-2000
			EP 1131113 A1	12-09-2001
			WO 0029043 A1	25-05-2000
			JP 2002529203 T	10-09-2002
			US 6517858 B1	11-02-2003
US 2001014717	A1	16-08-2001	US 2002193475 A1	19-12-2002
			EP 1347792 A2	01-10-2003
			WO 02058753 A2	01-08-2002
			AU 2449601 A	03-07-2001
			CA 2395199 A1	28-06-2001
			EP 1242130 A1	25-09-2002
			JP 2003517890 T	03-06-2003
			WO 0145763 A1	28-06-2001
			US 2001018469 A1	30-08-2001
			AU 4197401 A	15-10-2001
WO 9955396	A	04-11-1999	WO 0174415 A1	11-10-2001
			AT 219693 T	15-07-2002
			AU 760408 B2	15-05-2003
			AU 3563899 A	16-11-1999
			CA 2320259 A1	04-11-1999
			DE 69901927 D1	01-08-2002
			DE 69901927 T2	10-10-2002
			DK 1019111 T3	14-10-2002
			EP 1174157 A1	23-01-2002
			EP 1019111 A1	19-07-2000
			ES 2179646 T3	16-01-2003
			JP 3406903 B2	19-05-2003
			JP 2002512856 T	08-05-2002
			PT 1019111 T	31-10-2002
			WO 9955396 A1	04-11-1999
			US 2003031780 A1	13-02-2003
			US 6214901 B1	10-04-2001
WO 0224249	A	28-03-2002	US 6344035 B1	05-02-2002
			US 2002032434 A1	14-03-2002
US 6110483	A	29-08-2000	AU 2095002 A	02-04-2002
			WO 0224249 A2	28-03-2002
			US 2002065551 A1	30-05-2002
US 6110483	A	29-08-2000	AU 8159898 A	04-01-1999
			CN 1261288 T	26-07-2000
			EP 1003571 A2	31-05-2000
			JP 2002506369 T	26-02-2002
			WO 9858690 A2	30-12-1998
WO 03022324	A	20-03-2003		
			US 2002123505 A1	05-09-2002
			WO 03022807 A2	20-03-2003
			WO 03022324 A1	20-03-2003
			US 2003129215 A1	10-07-2003